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Introduction
While sildenafil citrate (Viagra, Pfizer Inc, New
York, NY) was the first phosphodiesterase type-5
inhibitor (PDE5i) developed in 1998, additional
agents such as vardenafil HCL (Levitra, Bayer-GSK,
Bayer ⁄GSK, Raritan, NJ) and tadalafil (Cialis, Lilly-
ICOS, Indianapolis, IN) have been subsequently
released. PDE5i are now the first-line treatment for
erectile dysfunction (ED) because of their well-estab-
lished safety, efficacy, and general ease of use. These
three drugs – all of which have been approved for
use by the European Medicines Agency (EMA) and
the United States Food and Drug Administration
(FDA) – induce an increase in arterial blood flow,
which leads to smooth muscle relaxation, vasodilata-
tion, and ultimately penile erection (1).
Compared with other PDE5i agents, tadalafil has
the longest in vivo half-life at 17.5 h, with drug effi-
cacy potentially lasting up to 36 h (2). PDE5i therapy
allows for two types of dosing: ‘on-demand’ before
sexual intercourse and ‘low-dose once daily’ intake
(3). Low-dose once daily PDE5i intake allows the
user to partake in sexual intercourse at any time,
eliminating the need to dose prior to intercourse. In
addition to the general improvement in sexual func-
tion, the results from several studies indicate that
tadalafil also improves voiding symptoms in individ-
uals with lower urinary tract symptoms (LUTS)
(4,5). However, no data exist comparing the
improvement in LUTS between on-demand and once
daily tadalafil dosing. In the present study, both the
efficacy and safety of erectile function and the
improvement of LUTS were compared between
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tract symptoms (LUTS) as well as safety of tadalafil dosed at 20 mg on-demand
and 5 mg once daily among ED patients. Materials and methods: A total of
194 ED patients visited between March 2010 and June 2011 were recruited. Out
of 194 individuals, 168 (86.6%) met inclusion criteria after completing the two-
week screening period (V0). The Patients were randomly allocated into two groups:
(i) 20 mg of tadalafil as needed (Group 1: n = 84, 50.0%) and (ii) 5 mg of tad-
alafil once daily (Group 2: n = 84, 50.0%). Blood pressure (BP), heart rate (HR)
and the five-item version of the International Index of Erectile Function (IIEF-5)
were assessed immediately before initiation of treatment (V1) and after four (V2)
and twelve weeks of treatment (V3). In men with an IPSS of ‡ 8 at V1, IPSS, max-
imal flow rate (Qmax) and post-void residual volume (PVR) were also assessed.
Results: Of the 168 patients, 134 (79.8%; Group 1: n = 68, 81.0%; Group 2:
n = 66, 78.6%) patients completed the trial. IIEF-5 improved in both groups, and
the mean change was larger in Group 2 at V3 (4.9 ± 4.2 vs. 6.5 ± 4.5;
p = 0.032) Similarly, though IPSS (with ‡ 8, n = 88, 65.7%; Group 1: n = 44,
64.7%; Group 2: n = 44, 66.7%) improved in both groups, the mean change was
larger in Group 2 at V3 ()2.8 ± 4.3 vs. )4.8 ± 4.1; p = 0.026). Qmax and PVR
did not differ significantly in either group. Conclusions: Once daily tadalafil was
more efficacious in treating both ED and LUTS than on-demand dosing. However,
no differences were observed between the two dosing schedules with regard to
the improvement in LUTS when stratified by improvement in ED. The side effects
were insignificant for both dosing schedules.
What’s known
Low-dose once daily phosphodiesterase type-5
inhibitor intake allows the user to partake in sexual
intercourse at any time, eliminating the need to
dose prior to intercourse. In addition to the general
improvement in sexual function, tadalafil also
improves voiding symptoms in individuals with
lower urinary tract symptoms. However, no data
exist comparing the improvement in lower urinary
tract symptoms between on-demand and once daily
tadalafil dosing.
What’s new
Both dosing schedules of tadalafil effectively
enhance sexual function and improve lower urinary
tract symptoms. When compared to on-demand
dosing, once daily dosing was more efficacious in
treating both erectile dysfunction and lower urinary
tract symptoms. No differences were observed
between the two dosing schedules with regard to
the improvement in lower urinary tract symptoms
when stratified by improvement in erectile
dysfunction.
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20 mg on-demand and 5 mg once daily tadalafil dos-
ing in patients with ED.
Material and methods
Patients and study design
In total, 194 patients who visited the five Impotence
Centers between March 2010 and May 2011 were
recruited for the present study. Institutional review
board approval was obtained prior to the clinical
study. Subjects were stratified by the five-item ver-
sion of the International Index of Erectile Function
(IIEF-5) score as follows: scores more than 18 were
classified as not having ED, scores between 14 and
17 as mild ED, scores between 10 and 13 as moder-
ate ED, and scores less than 10 as severe ED. This
stratification methodology was based on a study by
Ahn et al. (6) that established cut-off values for the
diagnosis of ED and validated the Korean version of
the IIEF-5. Inclusion criteria for subjects included:
(i) age of 20 years and above, (ii) an IIEF-5 score
< 18 on screening, and (iii) interest and ability to
participate in this clinical study. Exclusion criteria
were as follows: (i) a history of hypersensitivity reac-
tion to PDE5i, (ii) current use of medications that
affect erectile function (e.g. 5-alpha-reductase inhibi-
tor use within the previous month), (iii) any previ-
ous surgery for the treatment of ED, and (iv) current
use of nitrate preparations and NO providers.
All subjects visited a clinical center four times.
During the two-week screening visit (V0), physical
examinations were conducted to evaluate current
alcohol and tobacco use and obtain past medical his-
tory. At this time blood pressure (BP), heart rate
(HR), a 12-lead electrocardiogram (ECG), a complete
blood count, a blood chemistry panel, a routine uri-
nalysis, and IIEF-5 score were also obtained. Out of
194 individuals, 168 met inclusion criteria after com-
pleting V0.The Patients were randomly allocated into
two groups using computer random number genera-
tor: (i) patients dosed with 20 mg of tadalafil as
needed (Group 1: n = 84, 50.0%) and (ii) patients
dosed with 5 mg of tadalafil once daily (Group 2:
n = 84, 50.0%). Prior to the initial drug dosing (V1),
the following parameters were assessed: IIEF-5, the
Sexual Encounter Profile Questions 2 and 3 (SEP2
and SEP3), International Prostate Symptoms Score
(IPSS), BP, and HR. Maximum flow rate (Qmax) and
post-void residual volume (PVR) were evaluated in
addition to IIEF-5 in individuals with an IPSS of 8 or
greater and who had been given a-blockers (tamsulo-
sin or alfuzosin) to treat lower urinary tract symp-
toms secondary to benign prostatic hyperplasia
(LUTS ⁄BPH) for more than 3 months before the
study. Erectile function, voiding symptoms, BP, and
HR were all re-obtained four (V2) and twelve weeks
(V3) after study initiation. Any side effects related to
the medication were also recorded at this time. Dur-
ing the study period, individuals assigned to Group 1
were instructed to take 20 mg of tadalafil orally up to
two times a week as needed, while subjects assigned
to Group 2 were instructed to take 5 mg of tadalafil
orally every morning before breakfast. Subjects con-
currently taking a-blockers for LUTS/BPH were also
instructed to allow for a six hour interval between
medication administration. Regardless of group, par-
ticipants with compliance rates below 70% were
excluded. The primary outcome was improvement of
erectile function at V3. And the secondary outcome
was effectiveness of voiding symptoms.
Efficacy and safety measures
The efficacy of tadalafil in treating ED was evaluated
via IIEF-5, SEP2 (‘Were you able to insert your penis
into your partner’s vagina?’), SEP3 (‘Did your erec-
tion last long enough for you to have successful inter-
course?’) and the Global Assessment Questionnaire
(‘Do you note improvements in your erectile function
after oral intake of 20 mg of tadalafil on-demand or
5 mg once daily?’, GAQ). Specifically, the IIEF-5 is a
self-administered questionnaire, in which five
domains evaluate erectile function and intercourse
satisfaction, with higher scores in each domain repre-
senting better sexual function. The impact of tadalafil
on LUTS was evaluated in patients who scored 8 or
higher on the IPSS at the screening visit and who had
been given a-blockers to treat LUTS ⁄BPH for more
than 3 months before the study. In these groups of
patients, Qmax and PVR were also measured, as well
as IIEF-5 at V1. And IPSS, Qmax and PVR were also
reevaluated at V2 and V3. In addition, subjects who
scored 8 or higher on the IPSS at the screening visit
were divided into subgroups by the degree of
improvement in ED symptoms between V1 and V3
(Group A: IIEF-5 ‡ 5; Group B: IIEF-5 < 5), and
IPSS, Qmax and PVR were reevaluated after stratifi-
cation. Patient satisfaction was scored using Likert
scale: very satisfied, somewhat satisfied, somewhat
dissatisfied, and very dissatisfied. Patient’s statement
of satisfaction was regarded as either ‘very satisfied’
or ‘somewhat satisfied.’ All attempts were made to
ensure subject safety, including BP, HR, history tak-
ing, physical exams, side effect monitoring, and 12-
lead ECG to evaluate subjects’ risk of heart disease.
Statistical analysis
Characteristics of baseline were evaluated by intent-
to-treat analysis. Change of erectile function and
voiding symptom were evaluated by per protocol
analysis. All continuous variables were analysed by
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paired t-test (or Wilcoxon signed rank test), while
efficacy and stability were compared between the
two groups using an independent t-test (or Mann–
Whitney U test). Chi-square tests were used for
categorical variences. All data analysis and statistical
processing were performed using SPSS v.18.0 was
used for statistical analysis. In all cases, p values less
than 0.05 were defined as statistically significant.
Results
Patient population and demographics
Out of a total of 168 individuals, 134 patients
(79.8%; Group 1: n = 68, 81.0%; Group 2, n = 66,
78.6%) completed the full course of the twelve-week
clinical study. At V0, no statistically significant dif-
ferences were identified in demographics or other
baseline characteristics (Table 1). At V2, 20 men
(11.9%; Group 1: n = 9, 10.7%); Group 2: n = 11,
13.1%) dropped out of the study, while an additional
14 men (8.3%; Group 1: n = 7, 8.3%, Group 2:
n = 7, 8.3%) dropped out after V3, with Figure 1
listing the reasons for dropout.
Efficacy: Sexual function & satisfaction
Among the subjects in Group 1, the mean domain
score for IIEF-5 improved significantly: 9.2 ± 4.8 at
V1, 11.2 ± 5.4 at V2, and 14.1 ± 6.2 at V3
(p < 0.001 for V1–V2 and V1–V3). A similar statisti-
cally significant improvement was also observed
among subjects in Group 2: 9.4 ± 4.9 at V1,
11.9 ± 6.8 at V2, and 15.9 ± 6.2 at V3 (p < 0.001 for
V1–V2 and V1–V3). When compared at V3, Group
2 showed significantly more improvement than
Group 1 (4.9 ± 4.2 vs. 6.5 ± 4.5; p = 0.032)
(Table 2). At V1, SEP2 for Groups 1 and 2 were
27.9% and 25.8%, respectively (p = 0.776). SEP2
were 57.4% for Group 1 and 68.2% for Group 2 at
V2 (in both cases p < 0.001 vs. baseline; p = 0.195
for Group 1 vs. Group 2) and 64.7% and 81.8% at
V3 (in both cases p < 0.001 vs. baseline; p = 0.025
for Group 1 vs. Group 2) (Figure 2). At V1, SEP3
for Group 1 and Group 2 were 20.6% and 21.2%,
respectively (p = 0.929). SEP3 were 52.9% for Group
1 and 65.2% for Group 2 at V2 (in both cases
p < 0.001 vs. baseline; p = 0.151 for Group 1 vs.
Group 2), and 60.3% and 77.3% at V3 (in both cases
p < 0.001 vs. baseline; p = 0.034 for Group 1 vs.
Group 2) (Figure 3). At V2, 43 patients from both
Group 1 (63.2%) and Group 2 (65.2%) answered
‘yes’ to the GAQ questionnaire (p = 0.817). At V3,
50 subjects from Group 1 (76.5%) and 54 subjects
from Group 2 (81.8%) answered yes. No statistically
significant differences in the GAQ questionnaire
results were observed between the two groups at V3
(p = 0.250). On analysis of the patient satisfaction
results, 67 individuals (50.0%; Group 1: n = 32,
47.1%; Group 2: n = 35, 53.0%) reported being very
satisfied, 33 (24.6%; Group 1: n = 17, 25.0%; Group
2: n = 16, 24.3%) being somewhat satisfied, 23
(17.2%; Group 1: n = 14, 20.6%; Group 2: n = 9,
13.6%) being somewhat dissatisfied and 11 (8.2%;
Group 1: n = 5, 7.3%; Group 2: n = 6, 9.1%) being
very dissatisfied (p = 0.726). In total, 100 patients
(74.6%; Group 1: n = 49, 72.1%; Group 2: n = 51,
77.3%) reported being ‘satisfied’.
Efficacy: voiding symptoms
At V1, 44 patients in both Group 1 (64.7%) and
Group 2 (66.7%) had an IPSS ‡ 8. Over the course
of the study, IPSS significantly decreased in both
groups. Among individuals in Group 1 IPSS scores
decreased by 13.6 ± 6.1 at V1, 12.2 ± 6.8 at V2, and
10.8 ± 6.8 at V3 (p = 0.008 for V1–V2; p < 0.001
for V1–V3). Among individuals in Group 2 IPSS
scores decreased by 13.9 ± 6.1 at V1, 11.2 ± 6.2 at
V2, and 9.1 ± 6.4 at V3 (p < 0.001 for V1–V2 and
V1–V3).When compared at V3, the mean decrease in
IPSS was greater among individuals in Group 2
()2.8 ± 4.3 vs. )4.8 ± 4.1; p = 0.026) (Table 2). At
V1, 24 patients in Group 1 (35.3%) and 21 patients
in Group 2 (31.8%) had been given a-blockers to
Table 1 Patient characteristics at baseline
Characteristics Group 1 Group 2 p value
No. of patients 84 84
Age (years) 55.8 ± 8.9 55.4 ± 9.1 0.784
BMI (kg ⁄m2) 25.6 ± 2.3 25.8 ± 2.4 0.671
Duration of erectile
dysfunction (months)
7.9 ± 4.8 7.1 ± 4.2 0.256
Severity
Mild (%) 20 (23.8) 20 (23.8) 0.983
Moderate (%) 22 (26.2) 21 (25.0)
Severe (%) 42 (50.0) 43 (51.2)
Etiology of erectile dysfunction
Psycogenic (%) 10 (11.9) 11 (13.1) 0.965
Organic (%) 33 (39.3) 30 (35.7)
Mixed (%) 23 (27.4) 25 (29.8)
Unknown (%) 18 (21.4) 18 (21.4)
Underlying disease
BPH (%) 34 (40.5) 32 (38.1)
DM (%) 31 (36.9) 34 (40.5)
Hypertension or
cardiovascular
disease (%)
27 (32.1) 26 (31.0)
Pulmonary disease (%) 7 (8.3) 4 (4.8)
Neurologic disease (%) 5 (6.0) 5 (6.0)
BMI, body mass index; BPH, benign prostatic hyperplasia
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treat LUTS ⁄BPH for more than 3 months before the
study. Over the course of the study, IPSS signifi-
cantly decreased in both groups. Among individuals
in Group 1, IPSS scores decreased by 14.3 ± 8.2 at
V1, 13.5 ± 8.6 at V2, and 12.3 ± 8.2 at V3 (p =
0.003 for V1–V2; p < 0.001 for V1–V3). Among
individuals in Group 2, IPSS scores decreased by
15.3 ± 7.9 at V1, 12.2 ± 8.1 at V2, and 10.2 ± 8.1 at
V3 (p < 0.001 for V1–V2 and V1–V3). When com-
pared at V3, the mean decrease in IPSS was greater
among individuals in Group 2 ()2.1 ± 4.1 vs.
)5.1 ± 4.7; p = 0.030). No significant differences in
IPSS with regard to ED improvement was observed
in either subgroup, as determined by the degree of
improvement in ED symptoms (Group 1; Group A:
n = 22, 50.0%, Group B: n = 22, 50.0%; Group 2;
Group A: n = 24, 54.5%, Group B: n = 20, 45.5%)
(Table 3). Neither Qmax nor PVR differed signifi-
cantly in Group 1 or 2 (Table 2). Likewise, no signif-
icant differences in Qmax and PVR with regard to
ED improvement were observed in either subgroup,
as determined by the degree of improvement in ED
(Table 3).
Safety
Among those assigned to Group 1, adverse effects
occurred in three men (4.4%) at V2 and four men
(5.9%) at V3. In Group 2, three men (4.5%) experi-
enced adverse effects at V2 and three men (4.5%)at
V3. Facial flushing was the most common adverse
effect [n = 8, 6.0%; Group 1: n = 4, 5.9%, V2 ⁄V3: 2
(2.9%) ⁄ 2 (2.9%); Group 2: n = 4, 6.1%, V2 ⁄V3: 2
(3.0%) ⁄ 2 (3.0%)], followed by headache [n = 4,
3.0%; Group 1: n = 2, 2.9%, V2 ⁄V3: 1 (1.5%) ⁄ 1
(1.5%); Group 2: n = 2, 2.9%, V2 ⁄V3: 1 (1.5%) ⁄ 1
(1.5%)], and dizziness [n = 1, 0.7%; Group 1: V3: 1
(1.4%)]. A total of four men dropped out of the
study because of adverse effects (facial flushing in
three; Group 2: V2 ⁄V3: 2 ⁄ 1; headache in one; Group
1: V2: 1). Notably, no statistically significant differ-
Figure 1 The reasons for dropout
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ences in either of the variables relating to the cardio-
vascular system (BP and HR) occurred (Table 4).
Discussion
To date, several studies have examined the efficacy of
on-demand tadalafil dosing in the treatment of ED
(7–9), all of which have reported improvements in
sexual function, satisfaction and quality of life for
both subjects and their partners. Compared with
on-demand dosing, once daily tadalafil dosing has
the advantage of helping users manage voluntary sex-
ual activities. Eardley et al. (10), reported most indi-
viduals intending to have sexual intercourse initiate
sexual activity 30 min prior. Moreover, according to
the FEMALES study from Fisher et al. (11), 30% and
34% of men and women do not set a specific time
for sex. These two studies confirm that sexual activ-
ity is often not scheduled and does not happen at a
specific time. Accordingly, once daily tadalafil dosing
was proposed, and has since been evaluated by
several studies. Specifically, Althof et al. demon-
strated that men taking once daily 5 mg doses of
tadalafil reported better sexual function and
increased sexual satisfaction vs. placebo (12). In
another study from McVary et al. (13), once daily
dosing of tadalafil at 5 mg resulted in significantly
higher IIEF EF domain scores after 6 and 12 weeks
of treatment when compared with placebo.
Several studies have also compared the safety and
efficacy of the two dosing forms among ED patients.
In one study from McMahon et al. (14), 145 men
were divided into two groups. One group received
20 mg of tadalafil on-demand and the other group
was treated daily with 10 mg of tadalafil. At study
completion, the individuals receiving once daily
dosing exhibited better results in terms of IIEF,
SEP2, SEP3 and GAQ when compared with the
‘on-demand’ group. In another study, Ricardi et al.
(15) conducted once daily tadalafil dosing at 5 mg
with 20 mg of tadalafil on-demand among pros-
tate cancer patients treated with radiotherapy, with
Table 2 Comparison of IIEF-5, IPSS, Qmax and PVR of patients in V1*, V2 and V3 between two groups
Group 1 Group 2
p value§ p value–V1 V2 V3
p value
V1 V2 V3
p value
V1 vs.
V2
V1 vs.
V3
V1 vs.
V2
V1 vs.
V3
IIEF-5 9.2 ± 4.8 11.2 ± 5.4 14.1 ± 6.2 < 0.001 < 0.001 9.4 ± 4.9 11.9 ± 6.8 15.9 ± 6.2 < 0.001 < 0.001 0.838 0.032
IPSS 13.6 ± 6.1 12.2 ± 6.8 10.8 ± 6.8 0.008 < 0.001 13.9 ± 6.1 11.2 ± 6.2 9.1 ± 6.4 < 0.001 < 0.001 0.793 0.026
Qmax (ml ⁄ s) 14.3 ± 7.8 14.7 ± 7.0 14.4 ± 7.2 0.400 0.797 14.4 ± 8.2 14.8 ± 6.8 14.5 ± 7.5 0.921 0.659 0.789 0.609
PVR (ml) 38.6 ± 44.9 37.4 ± 36.3 37.7 ± 36.2 0.623 0.795 38.8 ± 38.5 37.3 ± 42.8 35.1 ± 34.1 0.692 0.296 0.990 0.579
*At the start of the study. 4 weeks. 12 weeks. §p value of baseline (Group 1 vs. Group 2). –p value of difference between V1 and V3 (Group 1 vs. Groups 2).
IIEF-5, International Index of Erectile Function-5; IPSS, International Prostate Symptom Score; Qmax, maximal flow rate; PVR, post-void residual volume
Figure 2 Successful penetration rate (SEP2) of Group 1
and Group 2. *p value of baseline (0.776; Group 1 vs.
Group 2). p value of each group (< 0.001; V1 vs. V2 and
V1 vs. V3). p value at V3 (0.025; Group 1 vs. Group 2)
Figure 3 Intercourse completion rate (SEP3) of Group 1
and Group 2. *p value of baseline (0.929; Group 1 vs.
Group 2). p value of each group (< 0.001; V1 vs. V2 and
V1 vs. V3). p value at V3 (0.034; Group 1 vs. Group 2)
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significant improvements in sexual function occur-
ring in both groups. Moreover, while both dosing
schedules were well tolerated, the once daily 5 mg
dosing group showed higher compliance and margin-
ally fewer side effects. The results from the current
study were not significantly different from any of the
previous reports, as tadalafil produced excellent
effects on all parameters, such as IIEF-5, SEP2 and
SEP3. When compared, the once daily group had an
increase in IIEF-5 of 6.5 ± 4.5 from baseline, an
increase larger than the 4.9 ± 4.2 observed in the on-
demand group. The once daily group also exhibited
better results in SEP2 and SEP3. Though not entirely
clear, the mechanism for the better results seen in
the once daily group likely relates to an enhancement
in endothelial function (16). In the case of chronic
treatment with PDE5i, functional tissue modification
occurs, involving the upregulation of transduction
mechanisms that activate muscarinic receptors and
induce endothelial nitric oxide synthesis (17).
Alternatively, these results may be explained by the
plasma concentration of tadalafil, even though no
direct correlation between plasma concentration and
efficacy has ever been verified. In one in vitro study
(18), a total tadalafil plasma concentration of
55 ng ⁄ml resulted in approximately 90% enzyme
inhibition, thus producing a reasonable pharmacody-
namic target. Furthermore, once daily 5 mg tadalafil
dosing maintained a plasma concentration of
55 ng ⁄ml longer than did 20 mg of tadalafil dosed
every 2.65 days, with such results providing a phar-
macologic rationale for low-dose once daily therapy.
In the present study, the two different tadalafil dos-
ing schedules were also compared with regard to
improvements in voiding function. Previously, epi-
demiologic data has correlated ED with LUTS ⁄BPH.
And, though no detailed mechanism for this correla-
tion has ever been proven, both are thought to share
a common pathophysiology (19), with four different
hypotheses proposed to explain this relationship: (i)
NOS ⁄NO levels are decreased or altered in prostate
and penile smooth muscle; (ii) autonomic hyperactiv-
ity and metabolic syndrome may affect LUTS, pros-
tate growth and ED; (iii) an alternate pathway
involving Rho-kinase activation ⁄ endothelin activity;
(iv) pelvic atherosclerosis as a underlying etiology for
LUTS and ED (20). Though a treatment agent for
ED, PDE5i agents also relieve LUTS, as PDE5i par-
tially reverses prostatic tissue contraction. Addition-
ally, these agents have been shown to increase cGMP,
ultimately producing an antiproliferative effect on
cultured human prostatic smooth muscle cells (21).
In one study, McVary et al. (13) evaluated the safety
and efficacy of once daily tadalafil dosing for the
treatment of LUTS ⁄BPH, showing that tadalafil was
associated with significant decreases in IPSS from
baseline. In another randomised, parallel-group, dou-
ble-blind, placebo-controlled study by Roehrborn
et al. (22), 1058 men with LUTS ⁄BPH were randomly
allocated to either receive once daily treatment with
placebo or tadalafil (2.5, 5, 10 or 20 mg) for
12 weeks, with all tadalafil groups exhibiting a signifi-
cant improvement in IPSS between baseline and
study termination. In this study, the effects of once
daily and on-demand tadalafil dosing on LUTS were
evaluated and compared. In both dosing schedules,
IPSS improved, though there was no effect on Qmax
and PVR in either group. When compared head-to-
head, both IPSS and erectile function improved more
in the once daily group than in the on-demand
group. We contend that these results can be explained
by the similarities in pathophysiology between ED
and LUTS ⁄BPH, with the improvements in LUTS
because of the two mechanisms explained above
(enhanced endothelial function and maintained
plasma concentration level). Nonetheless, this rela-
tionship has never been proven, and there have been
no studies on chronic treatment of PDE5i for LUTS.
Recently, PED5i ⁄a-blockers combination therapy
is stealing the spotlight in the treatment of
LUTS ⁄BPH because of the similarities in pathophysi-
ology between ED and LUTS ⁄BPH. And, the efficacy
and safety of tadalafil ⁄a-blockers combination ther-
apy for LUTS ⁄BPH patients already had been
improved by several studies (23,24). In the present
study, we also evaluated the impact of tadalafil on
LUTS in patients who had been given a-blockers to
treat LUTS ⁄BPH for more than 3 months before the
study. IPSS significantly improved in both groups,
but the mean change was larger in Group 2 at V3
similar to the whole group.
IPSS, Qmax and PVR were also examined before
and after treatment among the subgroups of patients
who reported LUTS, with these individuals grouped
according to the degree of improvement in IIEF-5.
We assessed both ED and LUTS based on the
assumption that they have a similar pathophysiology.
Notably, significant differences in parameters were
not observed in either group, though this may be
because of the smaller sample sizes of the subgroups.
In addition, there is a limitation in evaluating corre-
lation because the severity of ED was not taken into
consideration before treatments.
The major known side effects of tadalafil include
headache, dyspepsia, back pain, dizziness and flush-
ing (25). In the current study, the major side effects
reported were facial flushing, headache and dizziness,
with the severity intermediate and duration transient
in all cases. The number of subject dropouts was also
negligible, and no significant changes in hemody-
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namic parameters were observed in either group.
Under normal treatment circumstances, both tadala-
fil dosing schedules are considered safe, and no dif-
ferences in safety were observed between groups.
One notable limitation of the current study is the
lack of a placebo group. Given the different dosing
schedules of the two groups, incorporating a placebo
group was challenging. Other limitations include the
lack of evaluation of partner satisfaction. Yet, despite
these limitations, this study is significant as it is the
first prospective randomised study that evaluates the
effects of on-demand and once daily tadalafil dosing
on both erectile function and LUTS in the practical
clinical environment. Further studies with larger
sample sizes over longer periods of time are clearly
needed to better elucidate differences between the
two dosing schedules.
Conclusions
Both dosing schedules of tadalafil (5 mg once daily
and 20 mg on-demand) effectively treat ED, enhance
sexual function, and improve patient satisfaction.
Additionally, both dosing schedules also have been
shown to produce improvements in LUTS. When
compared with on-demand dosing, once daily tadala-
fil was more efficacious in treating both ED and
LUTS. Notably, no differences were observed
between the two dosing schedules with regard to the
improvement in LUTS when stratified by improve-
ment in ED. The side effects were negligible for both
dosing schedules.
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